Obsidian Therapeutics, Inc. Common Stock

Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company developing engineered cell and gene therapies. Its investigational therapy OBX-115 is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. The company uses a proprietary Cytodriver technology platform designed to regulate protein function with FDA-approved small-molecule drugs, and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to its investigational therapies is currently limited to clinical trial participation, and the company collaborates with other organizations to apply its platform technology. Obsidian Therapeutics was founded in 2015 and is based in Cambridge, Massachusetts.